Menorrhagia Treatment & Management
- Author: Julia A Shaw, MD, MBA, FACOG; Chief Editor: Michel E Rivlin, MD more...
Medical therapy for menorrhagia should be tailored to the individual. Factors taken into consideration when selecting the appropriate medical treatment include the patient's age, coexisting medical diseases, family history, and desire for fertility. Medication cost and adverse effects are also considered because they may play a direct role in patient compliance.
Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first-line medical therapy in ovulatory menorrhagia. Studies show an average reduction of 20-46% in menstrual blood flow. NSAIDs reduce prostaglandin levels by inhibiting cyclooxygenase and increasing the ratio of prostacyclin to thromboxane. NSAIDs are ingested for only 5 days of the entire cycle, limiting their most common adverse effect of stomach upset.
Oral contraceptive pills
Oral contraceptive pills (OCPs) are a popular first-line therapy for women who desire contraception. Menstrual blood loss is reduced as effectively as NSAID's secondary to endometrial atrophy. OCPs suppress pituitary gonadotropin release, preventing ovulation.
Common adverse effects include breast tenderness, breakthrough bleeding, nausea, and, possibly, related weight gain in some individuals.
A long-term combination of oral estradiol valerate and dienogest was found to be highly effective when compared with placebo in the treatment of women with heavy menstrual bleeding. In March 2012, dienogest/estradiol valerate (Natazia) was the first oral contraceptive approved by the FDA for heavy menstrual bleeding.
Progestin is the most frequently prescribed medicine for menorrhagia. Therapy with this drug results in a significant reduction in menstrual blood flow when used alone. Progestin works as an antiestrogen by minimizing the effects of estrogen on target cells, thereby maintaining the endometrium in a state of down-regulation. Common adverse effects include weight gain, headaches, edema, and depression.
Levonorgestrel intrauterine system
The levonorgestrel intrauterine system reduces menstrual blood loss by as much as 97% It is comparable to transcervical resection of the endometrium for reduction of menstrual bleeding[32, 33, 34] Adverse effects include uterine bleeding or spotting, headache, ovarian cysts, vaginitis, dysmenorrhea, and breast tenderness.
A study by Kim et al indicated that the presence of a large myoma increases the likelihood of treatment failure with either thermal balloon ablation or the levonorgestrel intrauterine system. The study involved 106 women with menorrhagia and either intramural or submucosal myomas, including 67 patients who underwent thermal balloon ablation and 39 who were treated with the levonorgestrel intrauterine system; follow-up lasted more than 12 months.
The investigators found that treatment failure (ie, hysterectomy at some time during follow-up or recurrence or persistence of menorrhagia within one year of treatment) for thermal balloon ablation for women with myomas of under 2.5 cm was 12%, compared with 28% for women with myomas that were less than 5 cm but greater than or equal to 2.5 cm, and 56% for women whose myomas were at least 5 cm in size. Those figures for women treated with the levonorgestrel intrauterine system were 14%, 29%, and 25%, respectively.
In the ECLIPSE trial, which compared the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system with standard medical care (ie, tranexamic acid, mefenamic acid, combined oestrogen-progestogen or progesterone alone) for menorrhagia, investigators noted that although both treatment groups had improved scores as measured by the Menorrhagia Multi-Attribute Scale (MMAS), significantly greater improvement occurred in the levonorgestrel intrauterine system group over a 2-year period. However, the differences between treatment groups were no longer signifcant at 5 years, and there was a similarly low proportion of women who required surgery in the groups. The investigators also indicated that the levonorgestrel intrauterine system was cost-effective in the short and medium term.
Gonadotropin-releasing hormone agonists
These agents are used on a short-term basis due to high costs and severe adverse effects. GnRH agonists are effective in reducing menstrual blood flow. They inhibit pituitary release of FSH and LH, resulting in hypogonadism. A prolonged hypoestrogenic state leads to bone demineralization and reduction of high-density lipoprotein (HDL) cholesterol.
Danazol competes with androgen and progesterone at the receptor level, causing amenorrhea in 4-6 weeks. Androgenic effects cause acne, decreasing breast size, and, rarely, lower voice.
These agents are given intravenously every 4 hours in patients with acute bleeding. A D&C procedure may be necessary if no response is noted in 24 hours. If menses slows, follow up with estrogen-progestin therapy for 7 days. This is followed by OCPs for 3 months.
Tranexamic acid (Lysteda) was the first nonhormonal product approved by the FDA (in November of 2009) for the treatment of heavy menstrual bleeding. It is a synthetic derivative of lysine that uses antifibrinolytic effects by inhibiting the activation of plasminogen to plasmin.
Tranexamic acid’s mechanism of action in treating heavy menstrual bleeding is by prevention of fibrinolysis and the breakdown of clots via inhibiting endometrial plasminogen activator.
In a double-blind, placebo-controlled study, women taking 3.9 g/d of tranexamic acid showed a significant reduction in menstrual blood loss and an increase in their health-related quality of life compared with those taking placebo. Common adverse effects include menstrual discomfort, headache, and back pain.
Surgical management has been the standard of treatment in menorrhagia due to organic causes (eg, fibroids) or when medical therapy fails to alleviate symptoms. Surgical treatment ranges from a simple D&C to a full hysterectomy.
Dilatation and curettage
A D&C should be used for diagnostic purposes. It is not used for treatment because it provides only short-term relief, typically 1-2 months.
This procedure is used best in conjunction with hysteroscopy to evaluate the endometrial cavity for pathology.
It is contraindicated in patients with known or suspected pelvic infection. Risks include uterine perforation, infection, and Asherman syndrome.
Resectoscopic endometrial ablation techniques
Transcervical resection of the endometrium
Transcervical resection of the endometrium (TCRE) has been considered the criterion standard cure for menorrhagia for many years.
This procedure requires the use of a resectoscope (ie, hysteroscope with a heated wire loop), and it requires time and skill.
The primary risk is uterine perforation.
Roller-ball endometrial ablation
Roller-ball endometrial ablation essentially is the same as TCRE, except that a heated roller ball is used to destroy the endometrium (instead of the wire loop).
It has the same requirements, risks, and outcome success as TCRE.
Satisfaction rates are equal to those of TCRE.
Endometrial laser ablation
Endometrial laser ablation requires Nd:YAG equipment and optical fiber delivery system.
The laser is inserted into the uterus through the hysteroscope while transmitting energy through the distending media to warm and eventually coagulate the endometrial tissue.
Disadvantages include the expense of the equipment (high), the time required for the procedure (long), and the risk of excessive fluid uptake from the distending media infusion and irrigating fluid.
This technique has largely been replaced by the nonresectoscopic systems (discussed below).
Nonresectoscopic endometrial ablation techniques
Thermal balloon therapy[5, 6]
A balloon catheter filled with isotonic sodium chloride solution is inserted into the endometrial cavity, inflated, and heated to 87°C for 8 minutes.
Uterine balloon therapy cannot be used in irregular uterine cavities because the balloon will not conform to the cavity.
Studies report a 90% satisfaction rate and a 25% amenorrhea rate. Long-term studies are ongoing.
Heated free fluid
HydroThermAblator (HTA) is an office procedure in which normal saline is infused into the uterus via the hysteroscope.
The solution is heated to 194°F (90°C) for 10 minutes under direct visualization.
This procedure requires only local anesthesia.
HTA may be used in patients with irregularly shaped endometrial cavities and/or fibroids.
Vaginal and skin burns are the most reported complications.
Cryoablation is the use of liquid nitrogen to freeze the endometrium. The procedure is performed in approximately 10 minutes under ultrasonographic guidance.
Patients usually experience 1 week of watery vaginal discharge postprocedure.
Risks include perforation and suboptimal ablation of the entire uterine cavity.
Microwave endometrial ablation alternative
Microwave endometrial ablation (MEA) was developed and has been used in Europe since 1996. It uses high-frequency microwave energy to cause rapid but shallow heating of the endometrium. Microwaves are selected so that they do not destroy beyond 6 mm in depth.
MEA requires 3 minutes of time and only local anesthetic. It is proving to be as effective as TCRE.
In a Japanese study, investigators found that multiple MEAs in the same region in women with adenomyosis and menorrhagia was more effective than conventional single ablation treatment, as well as resulted in higher patient satisfaction rates.
NovaSure system is a detailed microprocessor-based unit with a bipolar gold mesh electrode array. It contains a system for determining uterine integrity based upon the injection of CO2. The device is placed transcervically, the array is opened and electrical energy is applied for 80-90 seconds, desiccating the endometrium.
Endometrial ablation or resection preparation
A trial of medical therapy should have failed in patients considered for this therapy. The endometrium should be properly sampled and evaluated before surgery.
Patients should be pretreated with danazol or a GnRH analogue for 4-12 weeks before surgery to atrophy the endometrium, reducing surgical difficulty and time.
Success rates are similar to laser ablation techniques.
A 2005 Cochrane Review (updated in 2009) concluded that "overall the existing evidence suggests that success rates and complication profiles of newer techniques of ablation compare favourably with TCRE, although technical difficulties with new equipment need to be ironed out."[9, 39]
In an observational study (2010-2012) of 235 German women aged 18 years and older with menorrhagia and high or low surgical risk of complications who underwent radiofrequency endometrial ablation (RFEA), RFEA appeared to improve quality of life as well as resulted in high satisfaction among both groups of women. High-risk factors included anemia, coagulopathy, anticoagulation, thromboembolism, obesity, transplantation, malignancy, and severe cardiovascular/pulmonary disease.
Myomectomy can be useful in women who wish to retain their uterus and/or fertility.
Since myomectomy can be associated with large blood loss, this procedure is often reserved for cases of a single or few myomas.
Risks include large blood loss or recurrence.
Hysterectomy provides definitive cure for menorrhagia.
This procedure is more expensive and results in greater morbidity than ablative procedures.
The mortality rate ranges from 0.1-1.1 cases per 1000 procedures.
The morbidity rate is usually 40%.
Risks include those usually associated with major surgery.
A study by Roberts et al reviewed the cost effectiveness of first-generation and second-generation endometrial ablative techniques, hysterectomy, and the levonorgestrel-releasing intrauterine system (Mirena) for the treatment of heavy menstrual bleeding. Although the authors did not define "heavy menstrual bleeding," their analysis concluded that the most cost-effective initial treatment for menorrhagia that yielded the best quality of life was hysterectomy.
Tucker ME. Levonorgestrel system eases effects of menorrhagia. Medscape Medical News. Jan 09, 2013. Available at http://www.medscape.com/viewarticle/777406. Accessed: Jan 14, 2013.
Gupta J, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med. 2013 Jan 10. 368(2):128-37. [Medline].
DeCherney A, Polan ML. Hysteroscopic management of intrauterine lesions and intractable uterine bleeding. Obstet Gynecol. 1983 Mar. 61(3):392-7. [Medline].
Chullapram T, Song JY, Fraser IS. Medium-term follow-up of women with menorrhagia treated by rollerball endometrial ablation. Obstet Gynecol. 1996 Jul. 88(1):71-6. [Medline].
Meyer WR, Walsh BW, Grainger DA, et al. Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstet Gynecol. 1998 Jul. 92(1):98-103. [Medline].
Garza-Leal J, Pena A, Donovan A, et al. Clinical evaluation of a third-generation thermal uterine balloon therapy system for menorrhagia coupled with curettage. J Minim Invasive Gynecol. 2010 Jan-Feb. 17(1):82-90. [Medline]. [Full Text].
Goldrath MH. Evaluation of HydroThermAblator and rollerball endometrial ablation for menorrhagia 3 years after treatment. J Am Assoc Gynecol Laparosc. 2003 Nov. 10(4):505-11. [Medline].
[Guideline] ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 81, May 2007. Obstet Gynecol. 2007 May. 109(5):1233-48. [Medline].
Learman LA, Summitt RL Jr, Varner RE, et al. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol. 2004 May. 103(5 Pt 1):824-33. [Medline].
Wright RC. Hysterectomy: past, present, and future. Obstet Gynecol. 1969 Apr. 33(4):560-3. [Medline].
Showstack J, Lin F, Learman LA, et al. Randomized trial of medical treatment versus hysterectomy for abnormal uterine bleeding: resource use in the Medicine or Surgery (Ms) trial. Am J Obstet Gynecol. 2006 Feb. 194(2):332-8. [Medline].
Chen YJ, Li YT, Huang BS, Y, et al, for the Taiwan Association of Gynecology Systematic Review Group. Medical treatment for heavy menstrual bleeding. Taiwan J Obstet Gynecol. 2015 Oct. 54 (5):483-8. [Medline].
Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest. 1964. 16:244-8. [Medline].
Goldrath MH. Hysteroscopic endometrial ablation. Obstet Gynecol Clin North Am. 1995 Sep. 22(3):559-72. [Medline].
Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. Obstet Gynecol. 2001 Nov. 98(5 Pt 1):806-14. [Medline].
Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004 May. 190(5):1216-23. [Medline].
Lentz GM. Abnormal uterine bleeding. Katz VL, Lentz GM, Lobo RA, Gershenson DM, eds. Comprehensive Gynecology. 5th ed. Philadelphia, PA: Mosby; 2007. 915-32.
Glasser MH, Zimmerman JD. The HydroThermAblator system for management of menorrhagia in women with submucous myomas: 12- to 20-month follow-up. J Am Assoc Gynecol Laparosc. 2003 Nov. 10(4):521-7. [Medline].
Wilansky DL, Greisman B. Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol. 1989 Mar. 160(3):673-7. [Medline].
Collins JA, Schlesselman JJ. Hormone replacement therapy and endometrial cancer. Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 1999. 503-12.
[Guideline] James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009 Jul. 201(1):12.e1-8. [Medline].
Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998 Feb 14. 351(9101):485-9. [Medline].
Dodson MG. Use of transvaginal ultrasound in diagnosing the etiology of menometrorrhagia. J Reprod Med. 1994 May. 39(5):362-72. [Medline].
Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000 Oct 15. 89(8):1765-72. [Medline].
Shaw RW. Assessment of medical treatments for menorrhagia. Br J Obstet Gynaecol. 1994 Jul. 101 Suppl 11:15-8. [Medline].
Jurema M, Zacur H. Menorrhagia. UpToDate. Available at http://bit.ly/fHJVtw. Accessed: March 29, 2009.
Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991 Feb. 31(1):66-70. [Medline].
Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011 Apr. 117(4):777-87. [Medline].
Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990 Aug. 97(8):690-4. [Medline].
Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol. 2004 Dec. 104(6):1314-21. [Medline].
FDA approves intrauterine device for heavy menstrual bleeding. PR Newswire. Available at http://bit.ly/eKOVjr. 2009 Oct 01; Accessed: October 5, 2009.
Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Sep. 116(3):625-32. [Medline].
Kim JY, No JH, Kim K, et al. Effect of myoma size on failure of thermal balloon ablation or levonorgestrel releasing intrauterine system treatment in women with menorrhagia. Obstet Gynecol Sci. 2013 Jan. 56(1):36-40. [Medline]. [Full Text].
Gupta JK, Daniels JP, Middleton LJ, et al. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. Health Technol Assess. 2015 Oct. 19 (88):1-118. [Medline].
Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Oct. 116(4):865-75. [Medline].
Nakamura K, Nakayama K, Ishikawa M, et al. Efficacy of multiple microwave endometrial ablation technique for menorrhagia resulting from adenomyosis. J Obstet Gynaecol Res. 2015 Nov. 41 (11):1769-72. [Medline].
Lethaby A, Hickey M, Garry R, Penninx J. Endometrial resection / ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev. 2009 Oct 7. CD001501. [Medline].
Fischer F, Klapdor R, Gruessner S, Ziert Y, Hillemanns P, Hertel H. Radiofrequency endometrial ablation for the treatment of heavy menstrual bleeding among women at high surgical risk. Int J Gynaecol Obstet. 2015 Nov. 131 (2):123-8. [Medline].
Roberts TE, Tsourapas A, Middleton LJ, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ. 2011 Apr 26. 342:d2202. [Medline]. [Full Text].
Maybin JA, Critchley HO. Menstrual physiology: implications for endometrial pathology and beyond. Hum Reprod Update. 2015 Nov. 21 (6):748-61. [Medline].